Area of research
Neurology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Thymoma and KRAS, with related work in Immunology, Erlotinib, Thymic carcinoma. Notable publications include 'The Integrated Genomic Landscape of Thymic Epithelial Tumors', 'The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?', and 'Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase...'.
Anti–Interleukin-23 Autoantibodies in Adult-Onset Immunodeficiency
Prediction of cancer treatment response from histopathology images through imputed transcriptomics
The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy
Lymphocyte-driven regional immunopathology in pneumonitis caused by impaired central immune tolerance
The Integrated Genomic Landscape of Thymic Epithelial Tumors
Efficacy of milciclib (PHA-848125AC), a pan-cyclin d-dependent kinase inhibitor, in two phase II studies with thymic carcinoma (TC) and B3 thymoma (B3T) patients.
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small cell lung cancer after failure of prior chemotherapy and erlotinib
Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.